May 6, 2019
GenSight Biologics to present Data from the Reverse Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)
GenSIght will present results from the REVERSE Phase III clinical trial of GS010 at the 2019 American Academy of Neurology (AAN) Annual Meeting